SLC1A3 contributes to L‐asparaginase resistance in solid tumorsJianhui Sun, Reuven Agami, Remco Nagel et al.|The EMBO Journal|2019Cited by 74
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancerSander Mertens, Hugo J.G. Snippert, Maarten A. Huismans et al.|Cell Reports|2023Cited by 72
EZH2 Is Overexpressed in <i>BRCA1</i> -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based ChemotherapyJulian Puppe, Jos Jonkers, Mark Opdam et al.|Clinical Cancer Research|2019Cited by 46
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J. Frank, Sara Mainardi, Antonio Mulero‐Sánchez et al.|Cell Reports Medicine|2022Cited by 39
Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activityZiva Pogacar, Rodrigo Leite de Oliveira, Jackie Johnson et al.|PLoS ONE|2022Cited by 13